Dr. Galsky the Evolution of Standard Options in Urothelial Carcinoma

Partner | Cancer Centers | <b>The Tisch Cancer Institute</b>

Matthew Galsky, MD, discusses the evolution of standard of care treatment options in urothelial carcinoma.

Matthew Galsky, MD, professor of medicine (hematology and medical oncology) and urology, director of Genitourinary Medical Oncology, director of the Novel Therapeutics Unit, co-director of the Center of Excellence for Bladder Cancer, associate director for Translational Research, The Tisch Cancer Institute and the Icahn School of Medicine at Mount Sinai, discusses the evolution of standard of care treatment options in urothelial carcinoma.

In recent years, several novel therapies, such as enfortumab vedotin-ejfv (Padcev), sacituzumab govitecan-hziy (Trodelvy), and adjuvant nivolumab (Opdivo), were approved for use in patients with urothelial carcinoma, Galsky explains. Historically, standard treatment for this patient population was limited to a few effective chemotherapeutic regimens. However, these approvals have introduced novel therapies that span different drug classes and clinical disease states, Galsky says.

Additional research is needed to determine how to utilize these new therapies to optimize individual outcomes for patients. Additionally, drug development remains a key need in urothelial carcinoma to establish more effective and safer treatment options for patients, Galsky concludes.